What is Innoforce Pharmaceuticals?
Innoforce Pharmaceuticals operates as a specialized, partnership-focused biopharmaceutical entity dedicated to the rapid innovation and commercialization of advanced medicines. By maintaining a dual-presence in Hangzhou, China, and Rockville, Maryland, the company leverages a global footprint to provide comprehensive contract development and manufacturing organization (CDMO) services. Their core competencies encompass the GMP manufacturing of plasmid DNA, RNA, viral vectors, and cell-based products. Furthermore, through strategic joint ventures, Innoforce provides end-to-end support for antibody and protein drug development, positioning itself as an essential incubator for next-generation biological therapies.
How much funding has Innoforce Pharmaceuticals raised?
Innoforce Pharmaceuticals has raised a total of $156.6M across 1 funding round:
Series A
$156.6M
Series A (2021): $156.6M with participation from Advantech Capital, China Highrun Capital, and South China Venture Capital
Key Investors in Innoforce Pharmaceuticals
Advantech Capital
Advantech Capital is a private equity firm that specializes in innovation-driven growth capital, with a primary focus on the TMT, E-services, and healthcare sectors in China.
China Highrun Capital
China Highrun Capital is a financial advisory and investment firm that manages multiple funds, focusing on long-term value creation across diverse industries including medical and IT sectors.
South China Venture Capital
South China Venture Capital is an investment firm established in 2008 that manages both RMB and USD funds, with a strategic emphasis on early to growth-stage companies in biomedicine and artificial intelligence.
What's next for Innoforce Pharmaceuticals?
Looking ahead, the infusion of capital will likely be directed toward the expansion of Innoforce's manufacturing campus and the enhancement of its technical capabilities in gene and cell therapy production. As the company matures beyond its Series A stage, the focus will shift toward optimizing operational efficiencies and deepening its portfolio of global partnerships. By bridging the gap between laboratory innovation and large-scale commercial production, Innoforce is well-positioned to capitalize on the increasing demand for outsourced biopharmaceutical manufacturing, ensuring that cutting-edge treatments reach patients with greater speed and reliability.
See full Innoforce Pharmaceuticals company page
